GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Buyback Yield %

Aadi Bioscience (FRA:3350) Buyback Yield % : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aadi Bioscience's current buyback yield was 0.00%.


Aadi Bioscience Buyback Yield % Historical Data

The historical data trend for Aadi Bioscience's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Buyback Yield % Chart

Aadi Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Buyback Yield %
- -31.87 -24.18 -

Aadi Bioscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aadi Bioscience's Buyback Yield %

For the Biotechnology subindustry, Aadi Bioscience's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aadi Bioscience's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Buyback Yield % falls into.



Aadi Bioscience Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aadi Bioscience's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 45.916354
=0.00%

Aadi Bioscience's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 53.528156
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


Aadi Bioscience Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aadi Bioscience (FRA:3350) Business Description

Traded in Other Exchanges
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines